Brian McKernan joins as CEO to further advance Predicta’s clinical impact, including its non-invasive diagnostic for Multiple Myeloma “It’s an honor to join Predicta and our strong team of leading ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, today announced the availability of its first Laboratory ...
Predicta Biosciences is using precision medicine to diagnose and monitor multiple myeloma–and give doctors insights for better treatment plans. Over 35,000 Americans are diagnosed with a blood cancer ...
Tempus AI, Inc. and Predicta Biosciences recently expanded the commercial rollout of their co-branded GenoPredicta™ whole-genome sequencing assay, which combines flow cytometry and ultra-sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results